Cemiplimab boasts positive data in skin cancer trials

5 June 2018
2019_biotech_test_vial_discovery_big

Presenting at the annual meeting of the American Society of Clinical Oncology (ASCO), France’s Sanofi (Euronext: SAN) and USA-based Regeneron Pharmaceuticals (Nasdaq: REGN) have released new positive data for their oncology candidate cemiplimab.

The firms are developing the immuno-oncology treatment as part of a long-standing collaboration.

The results, which were published in the New England Journal of Medicine (NEJM), show that certain cutaneous squamous cell carcinoma (CSCC) patients had a 47.5% objective response after nearly eight months.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology